A randomized, phase II, biomarker-selected study comparing erlotinib to erlotinib intercalated with chemotherapy in first-line therapy for advanced non-small-cell lung cancer. [electronic resource]
Producer: 20111102Description: 3567-73 p. digitalISSN:- 1527-7755
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- Biomarkers, Pharmacological
- Cadherins -- metabolism
- Carboplatin -- administration & dosage
- Carcinoma, Non-Small-Cell Lung -- blood
- Drug Administration Schedule
- ErbB Receptors -- antagonists & inhibitors
- Erlotinib Hydrochloride
- Humans
- Lung Neoplasms -- blood
- Paclitaxel -- administration & dosage
- Proto-Oncogene Proteins -- metabolism
- Proto-Oncogene Proteins p21(ras)
- Quinazolines -- administration & dosage
- Survival Analysis
- Vimentin -- metabolism
- ras Proteins -- metabolism
No physical items for this record
Publication Type: Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.